US consumers are shielded from the cost of healthcare

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 16 No 8
Volume 16
Issue 8

In the article "Trustee warns that Medicare is heading for insolvency" (Oncology NEWS International July 2007, page 26), Dr. Thomas Saving made some excellent recommendations for changing how Medicare is financed.

In the article "Trustee warns that Medicare is heading for insolvency" (Oncology NEWS International July 2007, page 26), Dr. Thomas Saving made some excellent recommendations for changing how Medicare is financed. There is, however, one recommendation that Dr. Saving alluded to, but did not emphasize, when he stated that "beneficiaries are shielded from the fiscal realities of the medical care they consume."

This situation is further exacerbated by the care delivered, especially end-of-life-care, at the patient's directive. Thus, often patients and their families want everything done because that is the only way the patient can stay in the hospital and avoid home care and costs. Often these patient directives also economically benefit the caregivers.

In the current healthcare system, there are lots of winners. The only losers are the next generation of Americans, who will be left with the tab.

Unless we use incentives and disincentives in healthcare by denying payment and/or enforcing Dr. Saving's advice that "the first dollars spent on healthcare are the responsibility of the consumer," the US healthcare delivery system is unlikely to see much improvement.

Gilbert A. Lawrence, MD, DMRT, FRCRRadiation Oncology, Faxton Hospital Cancer CenterUtica, New York

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content